CAJ | 학술논문

目的:评价依折麦布联合阿托伐他汀对常规剂量他汀药物血脂控制不佳的冠心病患者的疗效.方法:选择服用常规剂量他汀药物血脂控制不佳的冠心病患者126例,随机分为依折麦布联合他汀药物治疗组62例(依折麦布10 mg/d+阿托伐他汀10 mg/d)和双倍剂量他汀药物治疗组64例(阿托伐他汀20 mg/d).持续24周测定两组患者的总胆固醇(TC),LDL-C,高密度脂蛋白胆固醇(HDL-C),菜油甾醇,7-烯胆甾烷醇和血浆前蛋白转化酶枯草溶菌素9(PSCK9)的含量的变化.结果:联合依折麦布治疗组LDL-C水平,菜油甾醇/7-烯胆甾烷醇比例和PSCK9水平明显低于双倍剂量阿托伐他汀治疗组.双倍剂量阿托伐他汀治疗组LDL-C水平在12周后逐渐回升而联合依折麦布治疗组LDL-C水平降低较为平稳.结论:对常规他汀剂量血脂控制不佳的患者联合依折麦布能有效抑制胆固醇的吸收和合成并且降低LDL-C效果明显优于单纯加大他汀药物剂量.
목적:평개의절맥포연합아탁벌타정대상규제량타정약물혈지공제불가적관심병환자적료효.방법:선택복용상규제량타정약물혈지공제불가적관심병환자126례,수궤분위의절맥포연합타정약물치료조62례(의절맥포10 mg/d+아탁벌타정10 mg/d)화쌍배제량타정약물치료조64례(아탁벌타정20 mg/d).지속24주측정량조환자적총담고순(TC),LDL-C,고밀도지단백담고순(HDL-C),채유치순,7-희담치완순화혈장전단백전화매고초용균소9(PSCK9)적함량적변화.결과:연합의절맥포치료조LDL-C수평,채유치순/7-희담치완순비례화PSCK9수평명현저우쌍배제량아탁벌타정치료조.쌍배제량아탁벌타정치료조LDL-C수평재12주후축점회승이연합의절맥포치료조LDL-C수평강저교위평은.결론:대상규타정제량혈지공제불가적환자연합의절맥포능유효억제담고순적흡수화합성병차강저LDL-C효과명현우우단순가대타정약물제량.
Objective:To assess LDL-C-lowering effect of ezetimibe-plus-atorvastatin in patients with coronary artery disease whole LDL-C levels were ≥ 70mg/dl after received conventional-dose statin. Method:Those patients(n=126)were randomly divided into two group and one of groups(n=62)received ezetimible 10 mg/d+atorvastatin 10 mg/d the other group(n=64)received double-dose atorvastatin(20 mg/d). The plasma concentrations of total cholesterol(TC),LDL-C,HDL-C,campesterol,lathosterol and protein convertase subtilisin/kexin type 9(PSCK9)of two groups were determined for 24 weeks. Result:The levels of LDL-C,PSCK9 and campesterol/lathosterol ratio were significantly lower in ezetimibe-plus-atorvastatin group compared to double-dose atorvastatin group. The LDL-C level of double-dose atorvastatin re-increased after 12 weeks,while LDL-C reduction was stable for 24 weeks. Conclusion:The patients with coronary artery disease whole LDL-C levels didn’t achieve therapeutic goal after received routine statin took better plus ezetimible,because ezetimibe-plus-atorvastatin could simultaneously inhibit the absorption and synthesis of cholesterol and provide stable decrease in LDL-C levels.